Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide
The Company had previously announced the first patient in the head and neck squamous cell carcinoma cohort of the study had been treated.
- The Company had previously announced the first patient in the head and neck squamous cell carcinoma cohort of the study had been treated.
- The BOLSTER trial is a basket trial being conducted at approximately 40 sites in North America, Europe, and Asia-Pacific.
- Total trial enrollment of 120 patients is expected to be completed in the second half of 2024.
- “We are excited to announce treatment of the first patient in the cholangiocarcinoma cohort of the BOLSTER trial.